Cetuximab combined with infusional 5-fluorouracil/folinic acid (5-FU/FA) and oxaliplatin in metastatic colorectal cancer (mCRC): A pooled analysis of COIN and OPUS study data.
Julien Taïeb
Consultant or Advisory Role - Merck KGaA
Honoraria - Merck KGaA
Tim Maughan
Honoraria - Merck KGaA
Carsten Bokemeyer
Consultant or Advisory Role - Merck KGaA
Honoraria - Merck KGaA
Research Funding - Merck KGaA
Eric Van Cutsem
Consultant or Advisory Role - Merck KGaA
Research Funding - Merck KGaA
Thomas Brodowicz
Honoraria - Merck KGaA
Gunnar Folprecht
Consultant or Advisory Role - Bristol-Myers Squibb; Merck KGaA; Roche
Honoraria - Merck KGaA; Novartis; Pfizer; Roche
Research Funding - Merck KGaA
Regina Esser
Employment or Leadership Position - Merck KGaA
Stock Ownership - Merck KGaA
Michael Schlichting
Employment or Leadership Position - Merck KGaA
Josep Tabernero
Consultant or Advisory Role - Amgen; Merck KGaA; Roche; Sanofi